Beta adrenoceptor blocking properties of MK-761

Area of Science:

• Pharmacology
• Cardiovascular Research

Background:

• MK-761 represents a novel class of compounds.
• It possesses both beta-adrenoceptor antagonist and vasodilating properties within a single molecule.

Purpose of the Study:

• To characterize the pharmacological profile of MK-761.
• To evaluate its in vitro and in vivo beta-adrenoceptor blocking and vasodilating activities.

Main Methods:

• In vitro studies using isolated cat heart papillary muscle and rat atria.
• In vivo studies in anesthetized dogs and reserpinized rats.
• Assessment of contractile force, heart rate, and blood pressure.

Main Results:

• MK-761 demonstrated in vitro beta-adrenoceptor blocking activity without depressing contractile force.
• It showed some intrinsic sympathomimetic activity in vivo.
• MK-761 was equipotent to timolol and pindolol in blocking cardiac and vascular beta-adrenergic receptors in dogs.
• The compound was not cardioselective and exhibited oral beta-adrenoceptor blocking activity in rats, reducing blood pressure.

Conclusions:

• MK-761 is a potent beta-adrenoceptor antagonist with vasodilating properties.
• Its unique profile, including lack of contractile depression and some intrinsic sympathomimetic activity, warrants further investigation.
• MK-761 demonstrates potential for managing cardiovascular conditions requiring beta-blockade and vasodilation.